First- and second-trimester screening for preeclampsia and intrauterine growth restriction

Clinics in Laboratory Medicine

Volumn 30, Issue 3, 2010, Pages 727-746

  Tuuli, Methodius G ^a   Odibo, Anthony O ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intrauterine growth restriction; Preeclampsia; Screening

Indexed keywords

ACTIVIN A; ADAM PROTEIN; ADAM12 PROTEIN; ADIPONECTIN; ALPHA FETOPROTEIN; ESTRIOL; INHIBIN A; LEPTIN; PADGEM PROTEIN; PLACENTA PROTEIN; PLACENTAL PROTEIN 13; SEX HORMONE BINDING GLOBULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

CLINICAL PRACTICE; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE PREDISPOSITION; DOPPLER ECHOGRAPHY; DOPPLER FLOWMETRY; DOWN SYNDROME; EARLY INTERVENTION; ENDOTHELIAL DYSFUNCTION; FIRST TRIMESTER PREGNANCY; GENOMICS; HUMAN; INSULIN RESISTANCE; INTRAUTERINE GROWTH RETARDATION; MATERNAL BLOOD; PATHOPHYSIOLOGY; PERINATAL MORBIDITY; PLACENTA CIRCULATION; PLACENTA PERFUSION; PLACENTA WEIGHT; PREDICTION; PREECLAMPSIA; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; UTERINE ARTERY; FEMALE; FETAL GROWTH RETARDATION; MASS SCREENING; PRE-ECLAMPSIA; PREGNANCY; PRENATAL DIAGNOSIS;

FEMALE; FETAL GROWTH RETARDATION; HUMANS; MASS SCREENING; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 77954804944     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.05.002     Document Type: Review

References (111)

1. McIntire D.D., Bloom S.L., Casey B.M., et al. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med 1999, 340(16):1234-1238.
2. Kaufmann P., Black S., Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003, 69(1):1-7.
3. Roberts J.M., Cooper D.W. Pathogenesis and genetics of pre-eclampsia. Lancet 2001, 357(9249):53-56.
4. Caniggia I., Winter J., Lye S.J., et al. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta 2000, 21(Suppl A):S25-S30.
5. Scifres C.M., Nelson D.M. Intrauterine growth restriction, human placental development and trophoblast cell death. J Physiol 2009, 587(Pt 14):3453-3458.
6. Burton G.J., Woods A.W., Jauniaux E., et al. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009, 30(6):473-482.
7. Roberts J.M., Taylor R.N., Musci T.J., et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989, 161(5):1200-1204.
8. Hsu C.D., Iriye B., Johnson T.R., et al. Elevated circulating thrombomodulin in severe preeclampsia. Am J Obstet Gynecol 1993, 169(1):148-149.
9. Mills J.L., DerSimonian R., Raymond E., et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA 1999, 282(4):356-362.
10. Taylor R.N., Crombleholme W.R., Friedman S.A., et al. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991, 165(4 Pt 1):895-901.
11. Vatten L.J., Skjaerven R. Is pre-eclampsia more than one disease?. BJOG 2004, 111(4):298-302.
12. Moldenhauer J.S., Stanek J., Warshak C., et al. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003, 189(4):1173-1177.
13. Egbor M., Ansari T., Morris N., et al. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 2006, 113(5):580-589.
14. Melchiorre K., Wormald B., Leslie K., et al. First-trimester uterine artery Doppler indices in term and preterm pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32(2):133-137.
15. von Dadelszen P., Magee L.A., Roberts J.M. Subclassification of preeclampsia. Hypertens Pregnancy 2003, 22(2):143-148.
16. The Lancet handbook of essential concepts in clinical research 2006, 79. Elsevier, Philadelphia (PA). K.F. Schulz, D.A. Grimes (Eds.).
17. Jaeschke R., Guyatt G.H., Sackett D.L. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994, 271(9):703-707.
18. Villar J., Say L., Shennan A., et al. Methodological and technical issues related to the diagnosis, screening, prevention, and treatment of pre-eclampsia and eclampsia. Int J Gynaecol Obstet 2004, 85(Suppl 1):S28-S41.
19. Chesley's hypertensive disorders in pregnancy 2009, Elsevier, Oxford (UK). 3rd edition. M.D. Lindheimer, J.M. Roberts, F.G. Cunningham (Eds.).
20. Lang T.A., Secic M. How to report statistics in medicine 1997, American College of Physicians, Philadelphia.
21. Studying a study and testing a test 1987, Little, Brown and Co, Boston. 2nd edition. R.K. Riegelman, R. Hirsch (Eds.).
22. Farag K., Hassan I., Ledger W.L. Prediction of preeclampsia: can it be achieved?. Obstet Gynecol Surv 2004, 59(6):464-482. [quiz: 485].
23. Conde-Agudelo A., Villar J., Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004, 104(6):1367-1391.
24. Pilalis A., Souka A.P., Antsaklis P., et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation. Ultrasound Obstet Gynecol 2007, 29(2):135-140.
25. Toal M., Keating S., Machin G., et al. Determinants of adverse perinatal outcome in high-risk women with abnormal uterine artery Doppler images. Am J Obstet Gynecol 2008, 198(3):330. e1-7.
26. Cnossen J.S., Morris R.K., ter Riet G., et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008, 178(6):701-711.
27. Conde-Agudelo A., Lindheimer M. Use of Doppler ultrasonography to predict pre-eclampsia. CMAJ 2008, 179(1):53. [author reply: 53-4].
28. Pretorius D.H., Nelson T.R., Baergen R.N., et al. Imaging of placental vasculature using three-dimensional ultrasound and color power Doppler: a preliminary study. Ultrasound Obstet Gynecol 1998, 12(1):45-49.
29. Konje J.C., Huppertz B., Bell S.C., et al. 3-dimensional colour power angiography for staging human placental development. Lancet 2003, 362(9391):1199-1201.
30. Hafner E., Metzenbauer M., Höfinger D., et al. Comparison between three-dimensional placental volume at 12 weeks and uterine artery impedance/notching at 22 weeks in screening for pregnancy-induced hypertension, pre-eclampsia and fetal growth restriction in a low-risk population. Ultrasound Obstet Gynecol 2006, 27(6):652-657.
31. Rizzo G., Capponi A., Pietrolucci M.E., et al. Effects of maternal cigarette smoking on placental volume and vascularization measured by 3-dimensional power Doppler ultrasonography at 11 + 0 to 13 + 6 weeks of gestation. Am J Obstet Gynecol 2009, 200(4):415. e1-5.
32. Matijevic R., Kurjak A. The assessment of placental blood vessels by three-dimensional power Doppler ultrasound. J Perinat Med 2002, 30(1):26-32.
33. Merce L.T., Barco M.J., Bau S. Reproducibility of the study of placental vascularization by three-dimensional power Doppler. J Perinat Med 2004, 32(3):228-233.
34. Tuuli M.G., Houser M., Odibo L., et al. Validation of placental vascular sonobiopsy for obtaining representative placental vascular indices by three-dimensionalpower Doppler ultrasonography. Placenta 2010, 31(3):192-196.
35. Merce L.T., Barco M.J., Bau S., et al. Assessment of placental vascularization by three-dimensional power Doppler " vascular biopsy" in normal pregnancies. Croat Med J 2005, 46(5):765-771.
36. Noguchi J., Hata K., Tanaka H., et al. Placental vascular sonobiopsy using three-dimensional power Doppler ultrasound in normal and growth restricted fetuses. Placenta 2009, 30(5):391-397.
37. Guiot C., Gaglioti P., Oberto M., et al. Is three-dimensional power Doppler ultrasound useful in the assessment of placental perfusion in normal and growth-restricted pregnancies?. Ultrasound Obstet Gynecol 2008, 31(2):171-176.
38. Raine-Fenning N.J., Welsh A.W., Jones N.W., et al. Methodological considerations for the correct application of quantitative three-dimensional power Doppler angiography. Ultrasound Obstet Gynecol 2008, 32(1):115-117. [author reply: 117-8].
39. Raine-Fenning N.J., Nordin N.M., Ramnarine K.V., et al. Determining the relationship between three-dimensional power Doppler data and true blood flow characteristics: an in-vitro flow phantom experiment. Ultrasound Obstet Gynecol 2008, 32(4):540-550.
40. Raine-Fenning N.J., Nordin N.M., Ramnarine K.V., et al. Evaluation of the effect of machine settings on quantitative three-dimensional power Doppler angiography: an in-vitro flow phantom experiment. Ultrasound Obstet Gynecol 2008, 32(4):551-559.
41. Schulten-Wijman M.J., Struijk P.C., Brezinka C., et al. Evaluation of volume vascularization index and flow index: a phantom study. Ultrasound Obstet Gynecol 2008, 32(4):560-564.
42. Viero S., Chaddha V., Alkazaleh F., et al. Prognostic value of placental ultrasound in pregnancies complicated by absent end-diastolic flow velocity in the umbilical arteries. Placenta 2004, 25(8-9):735-741.
43. Toal M., Chan C., Fallah S., et al. Usefulness of a placental profile in high-risk pregnancies. Am J Obstet Gynecol 2007, 196(4):363. e1-7.
44. Redman C.W. Current topic: pre-eclampsia and the placenta. Placenta 1991, 12(4):301-308.
45. Thomas R.L., Blakemore K.J. Evaluation of elevations in maternal serum alpha-fetoprotein: a review. Obstet Gynecol Surv 1990, 45(5):269-283.
46. Costa S.L., Proctor L., Dodd J.M., et al. Screening for placental insufficiency in high-risk pregnancies: is earlier better?. Placenta 2008, 29(12):1034-1040.
47. Cindrova-Davies T., Spasic-Boskovic O., Jauniaux E., et al. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. Am J Pathol 2007, 170(5):1511-1520.
48. Hung T.H., Charnock-Jones D.S., Skepper J.N., et al. Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol 2004, 164(3):1049-1061.
49. Tjoa M.L., Cindrova-Davies T., Spasic-Boskovic O., et al. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol 2006, 169(2):400-404.
50. Redman C.W. Platelets and the beginnings of preeclampsia. N Engl J Med 1990, 323(7):478-480.
51. Bosio P.M., Cannon S., McKenna P.J., et al. Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia. BJOG 2001, 108(7):709-715.
52. Morris R.K., Cnossen J.S., Langejans M., et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 2008, 8:33.
53. Ito N., Nomura S., Iwase A., et al. ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase. Biochem Biophys Res Commun 2004, 314(4):1008-1013.
54. Iba K., Albrechtsen R., Gilpin B., et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J Cell Biol 2000, 149(5):1143-1156.
55. Laigaard J., Sørensen T., Placing S., et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005, 106(1):144-149.
56. Spencer K., Cowans N.J., Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008, 28(3):212-216.
57. Cowans N.J., Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007, 27(3):264-271.
58. Poon L.C., Chelemen T., Granvillano O., et al. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008, 112(5):1082-1090.
59. Nicolaides K.H., Bindra R., Turan O.M., et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006, 27(1):13-17.
60. Chafetz I., Kuhnreich I., Sammar M., et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007, 197(1):35. e1-7.
61. Sekizawa A., Sekizawa A., Purwosunu Y., et al. PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci 2009, 16(4):408-413.
62. Cowans N.J., Spencer K., Meiri H. First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes. Prenat Diagn 2008, 28(2):121-125.
63. Romero R., Kusanovic J.P., Than N.G., et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008, 199(2):122. e1-11.
64. Gonen R., Shahar R., Grimpel Y.I., et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2008, 115(12):1465-1472.
65. Huppertz B., Sammar M., Chefetz I., et al. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008, 24(3):230-236.
66. Akolekar R., Syngelaki A., Beta J., et al. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn 2009, 29(12):1103-1108.
67. Maynard S., Epstein F.H., Karumanchi S.A. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008, 59:61-78.
68. Powers R.W., Roberts J.M., Cooper K.M., et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005, 193(1):185-191.
69. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658.
70. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003, 278(15):12605-12608.
71. Taylor R.N., Grimwood J., Taylor R.S., et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003, 188(1):177-182.
72. Crispi F., Llurba E., Domínguez C., et al. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008, 31(3):303-309.
73. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004, 89(2):770-775.
74. Teixeira P.G., Cabral A.C., Andrade S.P., et al. Placental growth factor (PlGF) is a surrogate marker in preeclamptic hypertension. Hypertens Pregnancy 2008, 27(1):65-73.
75. Lam C., Lim K.H., Karumanchi S.A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005, 46(5):1077-1085.
76. Moore Simas T.A., Crawford S.L., Solitro M.J., et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007, 197(3):244. e1-8.
77. Akolekar R., Zaragoza E., Poon L.C., et al. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32(6):732-739.
78. Kusanovic J.P., Romero R., Chaiworapongsa T., et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009, 22(11):1021-1038.
79. Savvidou M.D., Akolekar R., Zaragoza E., et al. First trimester urinary placental growth factor and development of pre-eclampsia. BJOG 2009, 116(5):643-647.
80. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50(1):137-142.
81. Signore C., Mills J.L., Qian C., et al. Circulating soluble endoglin and placental abruption. Prenat Diagn 2008, 28(9):852-858.
82. Baumann M.U., Bersinger N.A., Mohaupt M.G., et al. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008, 199(3):266. e1-6.
83. Hsu-Lin S., Berman C.L., Furie B.C., et al. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. J Biol Chem 1984, 259(14):9121-9126.
84. Larsen E., Celi A., Gilbert G.E., et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989, 59(2):305-312.
85. Halim A., Kanayama N., el Maradny E., et al. Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Am J Obstet Gynecol 1996, 174(1 Pt 1):272-277.
86. Banzola I., Farina A., Concu M., et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation. Prenat Diagn 2007, 27(11):1005-1010.
87. Spencer K., Yu C.K., Rembouskos G., et al. First trimester sex hormone-binding globulin and subsequent development of preeclampsia or other adverse pregnancy outcomes. Hypertens Pregnancy 2005, 24(3):303-311.
88. Williams M.A., Farrand A., Mittendorf R., et al. Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol 1999, 149(4):323-329.
89. Serin I.S., Ozçelik B., Basbug M., et al. Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2002, 100(2):143-145.
90. Schipper E.J., Bolte A.C., Schalkwijk C.G., et al. TNF-receptor levels in preeclampsia-results of a longitudinal study in high-risk women. J Matern Fetal Neonatal Med 2005, 18(5):283-287.
91. Leal A.M., Poon L.C., Frisova V., et al. First-trimester maternal serum tumor necrosis factor receptor-1 and pre-eclampsia. Ultrasound Obstet Gynecol 2009, 33(2):135-141.
92. Wolf M., Sandler L., Muñoz K., et al. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002, 87(4):1563-1568.
93. D'Anna R., Baviera G., Corrado F., et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG 2006, 113(11):1264-1269.
94. Moses E.K., Lade J.A., Guo G., et al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 2000, 67(6):1581-1585.
95. Harrison G.A., Humphrey K.E., Jones N., et al. A genomewide linkage study of preeclampsia/eclampsia reveals evidence for a candidate region on 4q. Am J Hum Genet 1997, 60(5):1158-1167.
96. Farina A., Sekizawa A., De Sanctis P., et al. Gene expression in chorionic villous samples at 11 weeks' gestation from women destined to develop preeclampsia. Prenat Diagn 2008, 28(10):956-961.
97. Founds S.A., Conley Y.P., Lyons-Weiler J.F., et al. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta 2009, 30(1):15-24.
98. Alberry M.S., Maddocks D.G., Hadi M.A., et al. Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol 2009, 200(1):98. e1-6.
99. Caramelli E., Rizzo N., Concu M., et al. Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction-a pilot study. Prenat Diagn 2003, 23(5):367-371.
100. Holzgreve W., Ghezzi F., Di Naro E., et al. Disturbed feto-maternal cell traffic in preeclampsia. Obstet Gynecol 1998, 91(5 Pt 1):669-672.
101. Lo Y.M., Leung T.N., Tein M.S., et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999, 45(2):184-188.
102. DiFederico E., Genbacev O., Fisher S.J. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol 1999, 155(1):293-301.
103. Cotter A.M., Martin C.M., O'leary J.J., et al. Increased fetal DNA in the maternal circulation in early pregnancy is associated with an increased risk of preeclampsia. Am J Obstet Gynecol 2004, 191(2):515-520.
104. Crowley A., Martin C., Fitzpatrick P., et al. Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenat Diagn 2007, 27(2):174-179.
105. NCI-NHGRI Working Group on Replication in Association Studies, Manolio T., Chanock S.J., et al. Replicating genotype-phenotype associations. Nature 2007, 447(7145):655-660.
106. Poon L.C., Maiz N., Valencia C., et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009, 33(1):23-33.
107. Plasencia W., Maiz N., Poon L., et al. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32(2):138-146.
108. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365(9461):785-799.
109. Espinoza J., Romero R., Nien J.K., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007, 196(4):326. e1-13.
110. Poon L.C., Kametas N.A., Maiz N., et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009, 53(5):812-818.
111. Poon L.C., Karagiannis G., Leal A., et al. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol 2009, 34(5):497-502.